Regent Assay advises IDE Vision on the acquisition of the MPSII Macular Pigment Screener from Elektron Eye Technology

Regent Assay has advised on the acquisition of the business and assets from Elektron Eye Technology by IDE Vision. The principal asset acquired is the MPSII, which was the world’s first commercially viable, patent-protected macular pigment measurement device which is used to determine the state of the macular pigment and has been shown to indicate the level of risk of a person developing Aged Related Macular Degeneration.

IDE Vision is led by David Smith, a medical devices industry veteran of over 25 years and previously the CEO of Elektron Eye Technologies. He has also held other senior roles at Coopervision, Carl Zeiss, Biocompatibles International plc, Tenaxis Medical Inc and others. David is supported by a senior management team that includes Esben Sorenson, an ophthalmic industry veteran with experience at Coopervision, Visaq, MESL and Ciba Vision.

David Smith has stated that “IDE’s vision is to develop the business internationally and to transition towards offering value-added easy to use and patient friendly systems which includes testing, selling supplements and monitoring the patient.”

The transaction was led by Ian Bussey and David Tucker at Regent Assay, with Moore Barlow providing legal support.